TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10229004

Group type: EXPERIMENTAL
Intervention: rHuEPO 150 U/kg per week
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: rHuEPO 450 U/kg per week
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: rHuEPO (both doses)
Number of subjects: 44
Study: 9019822

Group type: EXPERIMENTAL
Intervention: Antioxidant histochrome
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 1906791

Group type: EXPERIMENTAL
Intervention: Temafloxacin 600 mg twice daily for 7 days starting on day 1 of the contraceptive cycle
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control cycle (no temafloxacin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Temafloxacin
Number of subjects: 12
Study: 6654698

Group type: EXPERIMENTAL
Intervention: 18 g/d of sodium DL‐3‐hydroxybutyrate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Isoenergetic glucose
Number of subjects: 32
Study: 30734967

Group type: EXPERIMENTAL
Intervention: Community resource persons trained to provide culturally appropriate information on family planning
Number of subjects: 484

Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 484
Study: 29437667

Group type: EXPERIMENTAL
Intervention: WAVES intervention (healthy lifestyle programme)
Number of subjects: 1467

Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 1467
Study: 26820355

Group type: EXPERIMENTAL
Intervention: Systematic screening and optimal management of comorbidities
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study: 24448036

Group type: EXPERIMENTAL
Intervention: Weekly practice (once/week for four consecutive weeks)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Consecutive day practice (once/day for four consecutive days)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard group (control; no practice sessions)
Number of subjects: 110
Study: 22858715

Group type: EXPERIMENTAL
Intervention: 12 mg OTO-104
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 3 mg OTO-104
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 19321493

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg, up to 30 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study: 17563999

Group type: EXPERIMENTAL
Intervention: Antithrombin III concentrate
Number of subjects: 0
Study: 15466981

Group type: EXPERIMENTAL
Intervention: Combination tests of total and percent free PSA
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Total PSA
Number of subjects: 2069

Group type: COMPARATOR
Intervention: PSA > 4.0 ng/mL
Number of subjects: 2069
Study: 11353359

Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anesthetics (EMLA)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Single treatment groups (EMLA and Music)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study: 9443116

Group type: EXPERIMENTAL
Intervention: High-meat group (HMG) - mean meat content of 27 g/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low-meat group (LMG) - mean meat content of 10 g/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-meat group (HMG)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low-meat group (LMG)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 8059045

Group type: EXPERIMENTAL
Intervention: Isoflurane (group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol (group B)
Number of subjects: 80
Study: 3143436

Group type: EXPERIMENTAL
Intervention: Postoperative collaborative care with supervision by a geriatrician
Number of subjects: 108

Group type: COMPARATOR
Intervention: Routine orthopaedic care
Number of subjects: 108
Study: 29486879

Group type: EXPERIMENTAL
Intervention: Propofol TIVA (15.0 ± 4.7 mg/kg/h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane (mean EtISO of 1.12 ± 0.15%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol TIVA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study: 28146606

Group type: EXPERIMENTAL
Intervention: 4β-hydroxycholesterol (4βOHC)
Number of subjects: 79
Study: 26678437

Group type: EXPERIMENTAL
Intervention: Preventive intervention for falling (specific details not provided)
Number of subjects: 6668

Group type: EXPERIMENTAL
Intervention: Prioritization for falling (specific details not provided)
Number of subjects: 6668

Group type: EXPERIMENTAL
Intervention: Recurrent falls in the past year
Number of subjects: 6668

Group type: EXPERIMENTAL
Intervention: Severe fear-of-falling
Number of subjects: 6668

Group type: EXPERIMENTAL
Intervention: Use of a walking aid
Number of subjects: 6668
Study: 23652951

Group type: EXPERIMENTAL
Intervention: HP802‐247 (5M cells/mL) applied weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bacitracin ointment applied daily
Number of subjects: 0
Study: 20450412

Group type: EXPERIMENTAL
Intervention: 1 mg of oral micronized 17β-estradiol daily for 2 years
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 19876415

Group type: EXPERIMENTAL
Intervention: Thrombus-extraction catheters during carotid artery stenting
Number of subjects: 43

Group type: COMPARATOR
Intervention: Carotid artery stenting with distal embolic protection devices (DEPs) without prophylactic thrombus aspiration
Number of subjects: 43
Study: 17113932

Group type: EXPERIMENTAL
Intervention: EEG neurofeedback
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 15488112

Group type: EXPERIMENTAL
Intervention: Individual format of guided self‐change (I‐GSC)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Family involved format of guided self‐change (F‐GSC)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Choice of I‐GSC or F‐GSC
Number of subjects: 213

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 213
Study: 11101175

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide at doses ranging from 200 to 1600 microg administered twice daily for 12 to 20 weeks.
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study: 9299668

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study: 8394191

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (0.625 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 micrograms/day)
Number of subjects: 60
Study: 3538107

Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: phenelzine
Number of subjects: 137

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 137
Study: 30397984

Group type: EXPERIMENTAL
Intervention: Continuous low-dose isotretinoin (20 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conventional high-dose isotretinoin (0.5 mg/kg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both isotretinoin regimens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Posttreatment dermcidin levels
Number of subjects: 30
Study: 26869496

Group type: EXPERIMENTAL
Intervention: Open wedge osteotomy and fixation with plate (Hemax)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Crescentic osteotomy and fixation with a 3 mm cannulated screw
Number of subjects: 45
Study: 24779421

Group type: EXPERIMENTAL
Intervention: Profile suggesting the fellow student was 'high achieving'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Profile suggesting the fellow student was more normative in achievements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High social anxiety
Number of subjects: 0
Study: 23013946

Group type: EXPERIMENTAL
Intervention: Heparin-coated poliacrylonitrile AN69ST® membrane without systemic anticoagulation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Polysulfone HF80® dialyzer with standard anticoagulation (nadroparin)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Polysulfone HF80® dialyzer with nadroparin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Heparin-coated poliacrylonitrile AN69ST® membrane
Number of subjects: 6
Study: 21661459

Group type: EXPERIMENTAL
Intervention: Fine needle aspiration cytology (FNAC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Histopathological examination
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 40
Study: 17561739

Group type: EXPERIMENTAL
Intervention: Operative care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonoperative care
Number of subjects: 0
Study: 16285357

Group type: EXPERIMENTAL
Intervention: Docetaxel chemotherapy every three weeks combined with prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitoxantrone plus low-dose prednisone
Number of subjects: 0
Study: 11977645

Group type: EXPERIMENTAL
Intervention: Xeloda (capecitabine) at a dose of 2,510 mg/m2/d, bid, for two weeks followed by one week rest as one cycle.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Xeloda (capecitabine) in patients who had failed previous chemotherapy with taxanes and/or anthracycline.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Adverse reactions to Xeloda.
Number of subjects: 22
Study: 10563531

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Silymarin (Control)
Number of subjects: 31
Study: 7878283

Group type: EXPERIMENTAL
Intervention: Verapamil (5 to 10 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP) (5 to 20 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Adenosine triphosphate (ATP)
Number of subjects: 50
Study: 2086208

Group type: EXPERIMENTAL
Intervention: Fortified cereal (bovine haemoglobin concentrate, Fe: 14 mg/100 g of powder)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Regular solid foods (cooked vegetables and meat)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Fortified cereal with additional supplementation of 45 mg Fe for 90 days
Number of subjects: 188
Study: 457522

Group type: EXPERIMENTAL
Intervention: Sodium nitrate (NaNO3) aerosol inhalation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sodium chloride (NaCl) aerosol inhalation
Number of subjects: 21
Study: 31099264

Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercises three times a week for 12 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: General exercise protocol three times a week for 12 weeks
Number of subjects: 89
Study: 29063244

Group type: EXPERIMENTAL
Intervention: Fingolimod (0.5 mg daily)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Interferon beta-1b (250 µg every other day)
Number of subjects: 157
Study: 26463176

Group type: EXPERIMENTAL
Intervention: Community of Voices choir intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (wait 6 months to start the choir)
Number of subjects: 0
Study: 23896477

Group type: EXPERIMENTAL
Intervention: GSK2336805 (≥10 mg single dose)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GSK2336805 (various doses)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GSK2336805 (with food)
Number of subjects: 69

Group type: COMPARATOR
Intervention: GSK2336805
Number of subjects: 69
Study: 22051229

Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation (ORIF)
Number of subjects: 53

Group type: COMPARATOR
Intervention: External Fixation
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Volar Locking Plates
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Dorsal Plates
Number of subjects: 53
Study: 19151049

Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch (Synera, Rapydan)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Lidocaine/prilocaine cream (EMLA)
Number of subjects: 82
Study: 17142824

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (support level set at 10 cm H(2)O)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Spontaneous breathing (SB)
Number of subjects: 32
Study: 15969850

Group type: EXPERIMENTAL
Intervention: Presentation of the leaflet
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Presentation of the leaflet plus incentive for systematic processing
Number of subjects: 230

Group type: COMPARATOR
Intervention: No-leaflet control
Number of subjects: 230
Study: 12211502

Group type: EXPERIMENTAL
Intervention: Periodontal treatment before 28 weeks of gestation
Number of subjects: 400

Group type: COMPARATOR
Intervention: Periodontal treatment after delivery
Number of subjects: 400
Study: 10480624

Group type: EXPERIMENTAL
Intervention: Q allele carriers (n = 41, 39 KQ and 2 QQ)
Number of subjects: 121

Group type: COMPARATOR
Intervention: cultured skin fibroblasts from KQ versus KK subjects
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: KQ subjects (n = 11)
Number of subjects: 121
Study: 8686815

Group type: EXPERIMENTAL
Intervention: Propofol with low dose fentanyl
Number of subjects: 70

Group type: COMPARATOR
Intervention: Midazolam with high dose fentanyl
Number of subjects: 70
Study: 1753612

Group type: COMPARATOR
Intervention: Drug therapy alone (N=24)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Drug therapy in combination with hyperbaric oxygenation (N=27)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Drug therapy in combination with hemosorption (N=26)
Number of subjects: 77
Study: 6802557

Group type: EXPERIMENTAL
Intervention: Glucose System (TPN with intravenous glucose)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lipid System (TPN with 50% glucose + 50% intravenous fat)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glucose System
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lipid System
Number of subjects: 15
Study: 31287725

Group type: EXPERIMENTAL
Intervention: 3D virtual world classroom (VW group)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Traditional classroom (RL group)
Number of subjects: 215
Study: 29141663

Group type: EXPERIMENTAL
Intervention: Radiotherapy with quality assurance support
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Benchmark case radiotherapy planning
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Radiotherapy dose distribution
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Trial participation and QA processes
Number of subjects: 36
Study: 25760874

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily or 15 mg if creatinine clearance was 30-49 ml/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dose-adjusted Vitamin K antagonists (VKAs)
Number of subjects: 0
Study: 23432642

Group type: EXPERIMENTAL
Intervention: Glycine powder air-polishing (GPAP) for 5 sec in addition to oral hygiene instruction and non-surgical debridement.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-surgical debridement and oral hygiene instruction (Control group).
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (test and control).
Number of subjects: 24
Study: 22989394

Group type: EXPERIMENTAL
Intervention: Desmoteplase 90 μg/kg IV bolus injection
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Desmoteplase 70 and 90 μg/kg IV bolus injection
Number of subjects: 848

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 848
Study: 18829988

Group type: EXPERIMENTAL
Intervention: Vessel shrinkage
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Insulin requirements
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Apolipoprotein B
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Number of diseased vessels
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prior revascularization
Number of subjects: 45
Study: 17457267

Group type: EXPERIMENTAL
Intervention: Digital radiography by image intensifier
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Digital radiography
Number of subjects: 105
Study: 15111683

Group type: EXPERIMENTAL
Intervention: Ropinirole (0.5 to 6.0 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 12196868

Group type: EXPERIMENTAL
Intervention: Weekly courses of betamethasone until 33 weeks' gestation or delivery
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9658849

Group type: EXPERIMENTAL
Intervention: Positioning devices used during surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: No positioning devices used during surgery
Number of subjects: 24
Study: 7658273

Group type: EXPERIMENTAL
Intervention: Match‐to‐sample odorant discrimination task (MODT) for children aged 5 years and older.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Identification task (comparison with MODT).
Number of subjects: 92
Study: 2692970

Group type: EXPERIMENTAL
Intervention: Chewable cimetidine (200 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chewable antacid
Number of subjects: 80
Study: 347921

Group type: EXPERIMENTAL
Intervention: Nebulized racemic epinephrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 20
Study: 31012860

Group type: EXPERIMENTAL
Intervention: Smartphone app-based Mediterranean diet intervention (EXP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional standard-of-care counseling (SOC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both EXP and SOC
Number of subjects: 100
Study: 27912927

Group type: EXPERIMENTAL
Intervention: Supervised rehabilitation programme (30-min sessions 3 days per week for 8 weeks in the hospital)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home-based exercise programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervised rehabilitation programme
Number of subjects: 0
Study: 25415290

Group type: EXPERIMENTAL
Intervention: Gardasil (HPV vaccine)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Saline placebo vaccine
Number of subjects: 479
Study: 22815050

Group type: EXPERIMENTAL
Intervention: EV-077 0.0125 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: EV-077 0.125 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: EV-077 0.375 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: EV-077 0.75 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: EV-077 1.25 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: EV-077 1.875 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: EV-077 2.5 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: EV-077 (all doses)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: EV-077 (plasma concentrations above 20 ng/ml)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 21079937

Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atosiban
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19167698

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 84

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 84
Study: 17103040

Group type: EXPERIMENTAL
Intervention: Metronidazole (800 mg TID)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Satranidazole (300 mg TID with placebo at mealtime)
Number of subjects: 49
Study: 15554765

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 11677707

Group type: EXPERIMENTAL
Intervention: Practice-based anticoagulation management
Number of subjects: 452

Group type: COMPARATOR
Intervention: Hospital-based anticoagulation management
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 452
Study: 9141931

Group type: EXPERIMENTAL
Intervention: Midhumeral approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Axillary approach
Number of subjects: 60
Study: 8267110

Group type: EXPERIMENTAL
Intervention: Clozapine with fluoxetine (N = 6)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clozapine with valproic acid (N = 11)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clozapine alone (N = 17)
Number of subjects: 34
Study: 2961190

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29275118

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (500 mg/m2 every 8 weeks for up to 2 years)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 409
Study: 27120388

Group type: EXPERIMENTAL
Intervention: FOB Gold single-time testing
Number of subjects: 10000

Group type: COMPARATOR
Intervention: OC-Sensor single-time testing
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Both tests
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: FOB Gold test at increased cutoff concentrations
Number of subjects: 10000
Study: 26118519

Group type: EXPERIMENTAL
Intervention: TrP‐DN + EDU
Number of subjects: 12

Group type: COMPARATOR
Intervention: TrP‐DN
Number of subjects: 12
Study: 22886389

Group type: EXPERIMENTAL
Intervention: Disclosure of the DAWBA to practitioners
Number of subjects: 235

Group type: COMPARATOR
Intervention: Normal assessment (without DAWBA)
Number of subjects: 235
Study: 20810979

Group type: EXPERIMENTAL
Intervention: Higher dairy calcium intake (median for tertiles: 156.5, 358.0, and 582.9 mg/d)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Increased serum 25(OH)D (14.5, 21.2, and 30.2 ng/mL for tertiles)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Increase of 1 SD in dairy calcium intake
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Increase of 1 SD in serum 25(OH)D at the 6‐mo point
Number of subjects: 322
Study: 18391295

Group type: EXPERIMENTAL
Intervention: da Vinci robotic virtual reality simulator (dV-Trainer)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: offline dV-Trainer
Number of subjects: 0

Group type: COMPARATOR
Intervention: VR robotic surgery simulator
Number of subjects: 0